How are ALNY straddle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ALNY straddle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 38.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,105.12 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a ALNY straddle?

The breakeven for the ALNY straddle priced on this page is roughly $208.20 and $251.80 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ALNY market-implied 1-standard-deviation expected move in the same options snapshot is approximately 10.95%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current ALNY implied volatility affect this straddle?

ALNY ATM IV is at 38.20% with IV rank near 16.81%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

ALNY Straddle Strategy

ALNY (Alnylam Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing.

ALNY (Alnylam Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $29.97B, a trailing P/E of 36.93, a beta of 0.28 versus the broader market, a 52-week range of 197.81-495.55, average daily share volume of 1.4M, a public-listing history dating back to 2004, approximately 3K full-time employees. These structural characteristics shape how ALNY stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.28 indicates ALNY has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 36.93 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.

What is a straddle on ALNY?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

ALNY snapshot

As of August 14, 2026, spot at $228.10, ATM IV 38.20%, IV rank 16.81%, expected move 10.95%. The straddle on ALNY below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this straddle structure on ALNY specifically: ALNY IV at 38.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a ALNY straddle, with a market-implied 1-standard-deviation move of approximately 10.95% (roughly $24.98 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ALNY expiries trade a higher absolute premium for lower per-day decay. Position sizing on ALNY should anchor to the underlying notional of $228.10 per share and to the trader's directional view on ALNY stock.

ALNY straddle setup

The ALNY straddle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ALNY at $228.10 on that close, the first option leg uses a $230.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ALNY chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ALNY shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$230.00	$9.85
Buy 1	Put	$230.00	$11.95

ALNY straddle risk and reward

Net Premium / Debit: -$2,180.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$2,105.12
Breakeven(s): $208.20, $251.80
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

ALNY straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on ALNY. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$20,819.00
$50.44	-77.9%	+$15,775.69
$100.88	-55.8%	+$10,732.39
$151.31	-33.7%	+$5,689.08
$201.74	-11.6%	+$645.77
$252.18	+10.6%	+$37.53
$302.61	+32.7%	+$5,080.84
$353.04	+54.8%	+$10,124.15
$403.47	+76.9%	+$15,167.45
$453.91	+99.0%	+$20,210.76

When traders use straddle on ALNY

Straddles on ALNY are pure-volatility plays that profit from large moves in either direction; traders typically buy ALNY straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

ALNY thesis for this straddle

The market-implied 1-standard-deviation range for ALNY extends from approximately $203.12 on the downside to $253.08 on the upside. A ALNY long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ALNY IV rank near 16.81% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ALNY at 38.20%. As a Healthcare name, ALNY options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ALNY-specific events.

ALNY straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ALNY positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ALNY alongside the broader basket even when ALNY-specific fundamentals are unchanged. Always rebuild the position from current ALNY chain quotes before placing a trade.

Frequently asked questions

What is a straddle on ALNY?: A straddle on ALNY is the straddle strategy applied to ALNY (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ALNY stock at $228.10 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed ALNY chain strike and the premiums come straight from that session's bid/ask midpoint.
How are ALNY straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ALNY straddle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 38.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,105.12 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ALNY straddle?: The breakeven for the ALNY straddle priced on this page is roughly $208.20 and $251.80 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ALNY market-implied 1-standard-deviation expected move in the same options snapshot is approximately 10.95%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on ALNY?: Straddles on ALNY are pure-volatility plays that profit from large moves in either direction; traders typically buy ALNY straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current ALNY implied volatility affect this straddle?: ALNY ATM IV is at 38.20% with IV rank near 16.81%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.